1.     Schulz R, Bethauser H, Stempka L, Heilig B, Moll A, and Hufner M. Evidence for immunological differences between circulating and tissue-derived thyroglobulin in men. Eur J Clin Invest 1989; 19:459-63.

2.     Di Jesu B, Pereira R, Consiglio E, Formisano S, Satrustegui J, and Sandoval IV. Demonstration of a Ca2+ requirement for thyroglobulin dimerization and export to the golgi complex. Eur J Biochem 1998; 252:583-90.

3.    Demers LM, and Spencer CA. Laboratory Medicine Practice Guidelines: Laboratory Support for the Diagnosis and Monitoring of Thyroid Disease. Thyroid 2003;13:57-67.

4.     Spencer CA, Takeuchi M, and Kazarosyan M. Current Status and Performance Goals for Serum Thyroglobulin Assays. Clin Chem 1996;42:164-73.

5.     Pacini F, Mariotti S, Formica N, and Elisei R. Thyroid autoantibodies in thyroid cancer: Incidence and relation­ship with tumor outcome. Acta Endocrinol 1988;119:373-80.

6.     Rubello D, Casara D, Girelli ME, Piccolo M, and Busnardo B. Clinical meaning of circulating antithyroglobulin anti-bodies in differentiated thyroid cancer: a prospective study. J Nucl Med 1992;33:1478-80.

7.     Spencer CA, Wang C, Fatemi S, Guttler RB, Takeuchi M, and Kazarosyan M. Serum Thyroglobulin Autoantibodies: Prevalence, influence on serum thyroglobulin measure­ment and prognostic significance in patients with differ­entiated thyroid carcinoma. J Clin Endocrinol Metab 1998;83:1121-7.

8.    Feldt-Rasmussen U, Petersen PH, Blaabjerg O, and Horder M. Long-term variability in serum thyroglobulin and thy-roid related hormones in healthy subjects. Acta Endocrinol (Copenh) 1980;95:328-34.

9.     Feldt-Rasmussen U, and Schlumberger M. European inter­laboratory comparison of serum thyroglobulin measure­ment. J Endocrinol Invest 1988;11:175-81.

10.  Feldt-Rasmussen U, Profilis C, Colinet E, Black E, Bornet H, Bourdoux P, Carayon P, Ericsson UB, Koutras DA, Lamas de Leon L, DeNayer P, Pacini F, Palumbo G, Santos A, Schlumberger M, Seidel C, Van Herle AJ, and D. JJM. Human thyroglobulin reference material (CRM 457) 2nd part: Physicochemical characterization and certification. Ann Biol Clin 1996;54:343-348.

11.  Mazzaferri EL, and Jiang SM. Long-term impact of initialsurgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28.

12.  Schlumberger M, Travagli JP, Fragu P, Gardet P, Lumbruso J, and Parmentier C. Follow-up of patients with differen­tiated thyroid carcinoma. Experience at Institut Gustave-Roussy, Villejuif. Eur J Cancer Clin Oncol 1988;24:345-50.

13.  Torrens JI, and Burch HB. Serum thyroglobulin measure­ment. Utility in clinical practice. Endocrinol Metab Clin N Amer 2001;30:429-67.

14.  Rodbard, D. Statistical estimation of the minimal detect­able concentration ("sensitivity") for radioligand assays. Anal Biochem 1978;90:1-12.

15.  Spencer CA, Takeuchi M, and Kazarosyan M. Current sta­tus and performance goals for serum thyrotropin (TSH) assays. Clinical Chemistry 1996;42:141-145.

16.  Vogeser M, Weigand M, Fraunberger P, Fischer H, and Cremer P. Evaluation of the ADVIA Centaur TSH-3 assay. Clin Chem Lab Med 2000;38:331-4.

17.  Fatemi S, Delaney M, Guttler R, LoPresti J, Singer P, Bergoglio L, Nicoloff J, and Spencer C. The First-Year Post-Thyroidectomy Serum Tg Concentration (During L­T4 Treatment) Predicts Long-Term Recurrence Risk in Patients with Papillary Thyroid Carcinoma (PTC). J Clin Endocrinol Metab 2004;manuscript in preparation.

18.  Saboori AM, Rose NR, Kuppers RC, Butscher WG, Bresler HS, and Burek CL. Immunoreactivity of multiple molecu­lar forms of human thyroglobulin. Clin Immunol Immunopathol 1994;72:121-8.

19.  Sugawa H, Smith E, Imura H, and Mori T. A thyroid can­cer specific monoclonal antibody which recognizes cryp­tic epitope(s) of human thyroglobulin. Mol Cell Endocrinol 1993;93:207-11.

20.  Fatemi S, Nicoloff J, LoPresti J, Guttler R, and Spencer C. Clinical significance of serial serum Tg autoantibody (TgAb) patterns in patients with differentiated thyroid cancers (DTC). 12th. International Congress of Thyroido­logy. 2000; Kyoto.

21.  Franke WG, Zophel K, Wunderlich GR, Mat R, Kuhne A, Schimming C, Kropp J, and Bredow J. Thyroperoxidase: a tumor marker for post-therapeutic follow-up of differen­tiated thyroid carcinomas? Results of a time course study. Cancer Detect Prev 2000;24:524-30.

22.  Massart C, and Maugendre D. Importance of the detection method for thyroglobulin antibodies for the validity of thyroglobulin measurements in sera from patients with Graves' disease. Clin Chem 2002;48:102-7.

23.  Spencer CA. Recoveries cannot be used to authenticate thyroglobulin (Tg) measurements when sera contain Tg autoantibodies. Clin Chem 1996;42:661-3.

24.  Mariotti S, Barbesino G, Caturegli P, Marino M, Manetti L, Pacini F, Centoni R, and Pinchera A. Assay of thyroglob­ulin in serum with thyroglobulin autoantibodies: an unob­tainable goal? J Clin Endocrinol Metab 1995;80:468-72.

25.  Levinson SS. The nature of heterophilic antibodies and their role in immunoassay interference. J Clin Immuno­assay 1992;15:108-15.

26.  Preissner CM, O'Kane DJ, Singh RJ, Morris JC, and GrebeSKG. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J Clin Endo­crinol Metab 2003;88:3069-74.

27.  Benvenga S, Burek CL, Talor M, Rose NR, and Trimarchi F. Heterogeneity of the thyroglobulin epitopes associatedwith circulating thyroid hormone autoantibodies in Hashimoto's thyroiditis and non-autoimmune thyroid dis­eases. J Endocrinol Invest 2002;25:977-82.

28.  Schneider AB, and Pervos R. Radioimmunoassay of human thyroglobulin: effect of antithyroglobulin autoan­tibodies. J Clin Endocrinol Metab 1978;47:126-37.

29.  Feldt-Rasmussen U, and Rasmussen AK. Serum thy­roglobulin (Tg) in presence of thyroglobulin autoantibod­ies (TgAb). Clinical and methodological relevance of the interaction between Tg and TgAb in vitro and in vivo. J Endocrinol Invest 1985;8:571-6.

30.  Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, Molinaro E, and Pinchera A. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic 131I whole body scan: Comparison of patients treated with high 131I activities versus untreated patients. J Clin Endocrinol Metab 2001;86:4092-7.

31.  Koh JM, Kim ES, Ryu JS, Hong SJ, Kim BB, and Shong YK. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study. Clin Endocrinol 2003;58:421-7.

32.  Hollowell JG, Staehling NW, Hannon WH, Flanders WD, Gunter EW, Spencer CA, and Braverman LE. Serum thy­rotropin, thyroxine, and thyroid antibodies in the United States population (1988 to 1994): NHANES III. J Clin Endocrinol Metab 2002;87:489-99.

33.  Bachelot A, Cailleuz AF, Klain M, Baudin E, Ricard M, Bellon N, Caillou B, Travagli JP, and Schlumberger M. Relationship between tumor burden and serum thy­roglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid 2002;12:707-11.

34.  Gardner DF, Rothman J, and Utiger RD. Serum thyroglob­ulin in normal subjects and patients with hyperthyroidism due to Graves' disease: effects of T3, iodide, 131I and antithyroid drugs. Clin Endocrinol 1979;11:585-94.

35.  Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F, and DeGroot LJ. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994;79:98-105.

36.  Savelli G, Chiti A, Rodari M, Schreiner F, Maccauro M, Aliberti G, Gerali A, and Bombardieri E. Predictive value of thyroglobulin changes for the efficacy of thyroid rem­nant ablation. Tumori 2001;87:42-6.

37.  Antonelli A, Miccoli P, Fallahi P, Grosso M, Nesti C, Spinelli C, and Ferrannini E. Role of neck ultrasonogra­phy in the follow-up of children operated on for papillary cancer. Thyroid 2003;13:479-84.

38.  Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, and Pinchera A. A consensus report on the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocri­nol Metab 2003;88:1433-41.

39.  Torlontano M, Crocetti U, D'Aloiso L, Bonfitto N, Di Giorgio A, Modoni S, Valle G, Frusciante V, Bisceglia M, Filetti S, Schlumberger M, and Trischitta V. Serum thy­roglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. Eur J Endocri­nol 2003;148:19-24.

40.  Hocevar M, and Auersperg M. Role of serum thyroglobu-lin in the pre-operative evaluation of follicular thyroid tumors. Eur J Surg Oncol 1998;24:553-7.

41.  Ericson UB, Tegler L, Lennquist S, Christensen SB, Stahl E, and Thorell JI. Serum thyroglobulin in differentiated thy­roid carcinoma. Acta Chir Scand 1984;150:367-75.

42.  Bayraktar M, Ergin M, Boyacioglu A, and Demir S. A pre­liminary report of thyroglobulin release after fine needle aspiration biopsy of thyroid nodules. 18 J Int Med Res 1990;:253-5.

43.  Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, and Ridgway EC. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or can­cer. J Clin Endocrinol Metab 1999;84:3877-85.

44.  Spencer CA, LoPresti JS, Fatemi S, and Nicoloff JT. Detection of residual and recurrent differentiated thyroid carcinoma by serum Thyroglobulin measurement. Thyroid 1999;9:435-41.

45.  Schlumberger M, C. P., Fragu P, Lumbroso J, Parmentier C and Tubiana M,. Circulating thyrotropin and thyroid hor­mones in patients with metastases of differentiated thy­roid carcinoma: relationship to serum thyrotropin levels. J Clin Endocrinol Metab 1980;51:513-9.

46.  Spencer C, and Fatemi S. Thyroglobulin Measurements in Thyroid Cancer Evaluation and Surveillance. In Current Concepts in Thyroid Disorders and Pathogenesis and Treatment of Thyroid Neoplasms. 2004; Editor: Bryan Haugen. Elsevier Sciences, New York.